Abstract
Sugammadex is the first selective relaxant-binding agent (SRBA) designated to reverse the neuromuscular blocking agent (NMBA) which is currently available in Japan.
This drug is rapidly effective against profound neuromuscular block even if NMBA is administered continuously or overdosed.
Neuroprotective operations with limited administration of NMBA to monitor and detect neuromuscular activity to protect against nerve injury are increasingly common. In these operations, patients must be immobilized with balanced anesthesia using analgesics and sedatives.
However, there have been reports of anaphylaxis caused by sugammadex. It is therefore better to use neuromuscular antagonists to require the recovery of neuromuscular blockade from carefully assessing by neuromuscular monitoring and clinical signs.
